Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3067303rdf:typepubmed:Citationlld:pubmed
pubmed-article:3067303lifeskim:mentionsumls-concept:C0034380lld:lifeskim
pubmed-article:3067303lifeskim:mentionsumls-concept:C0150097lld:lifeskim
pubmed-article:3067303lifeskim:mentionsumls-concept:C0006938lld:lifeskim
pubmed-article:3067303lifeskim:mentionsumls-concept:C0022860lld:lifeskim
pubmed-article:3067303lifeskim:mentionsumls-concept:C0005823lld:lifeskim
pubmed-article:3067303lifeskim:mentionsumls-concept:C2587213lld:lifeskim
pubmed-article:3067303pubmed:issue5lld:pubmed
pubmed-article:3067303pubmed:dateCreated1989-3-28lld:pubmed
pubmed-article:3067303pubmed:abstractTextThe purpose of this multicenter randomised, double-blind and cross-over study was to compare the antihypertensive effects of labetalol (L) and captopril (C) in 42 moderate hypertensive patients (mean age: 52 years). The drugs were given during two 4-weeks periods at the end of which the systolic (SBP) and diastolic blood pressures (DBP) were measured at rest in supine and standing positions. The assessment of the quality of life was realized with 4 scales completed by the practitioner [anxiety, depression, well-being, visual analog scale (VAS)] and 4 scales of auto-assessment completed by the patient [2 VAS, well-being, sub-scale of pleasure]. At the end of the first treatment's period (D28), both drugs had decreased significantly supine SBP and DBP (p less than 0.001), standing DBP (L = p less than 0.01; C = p less than 0.05), while only L lowered supine SBP (p less than 0.01). The cross-over analysis was unable to conclude, due to the number of patients and a significant interaction which reduced its power. Thus the effect of the first treatment's period seemed to influence the efficacy of the second one. The percentages of patients with a controlled BP were respectively: after 4 weeks of treatment, L = 61 p. 100 vs C = 42 p. 100 and at the end of study (D56), L = 67 p. 100 vs C = 64 p. 100. The cross-over analysis didn't show any difference between the effects of L and C on the quality of life.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:3067303pubmed:languagefrelld:pubmed
pubmed-article:3067303pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3067303pubmed:citationSubsetIMlld:pubmed
pubmed-article:3067303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3067303pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3067303pubmed:statusMEDLINElld:pubmed
pubmed-article:3067303pubmed:issn0248-8663lld:pubmed
pubmed-article:3067303pubmed:authorpubmed-author:JouventRRlld:pubmed
pubmed-article:3067303pubmed:authorpubmed-author:CarréAAlld:pubmed
pubmed-article:3067303pubmed:authorpubmed-author:PappoMMlld:pubmed
pubmed-article:3067303pubmed:authorpubmed-author:d'AllensHHlld:pubmed
pubmed-article:3067303pubmed:authorpubmed-author:BaruchPPlld:pubmed
pubmed-article:3067303pubmed:authorpubmed-author:PetetinNNlld:pubmed
pubmed-article:3067303pubmed:issnTypePrintlld:pubmed
pubmed-article:3067303pubmed:volume9lld:pubmed
pubmed-article:3067303pubmed:ownerNLMlld:pubmed
pubmed-article:3067303pubmed:authorsCompleteYlld:pubmed
pubmed-article:3067303pubmed:pagination545-53lld:pubmed
pubmed-article:3067303pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:meshHeadingpubmed-meshheading:3067303-...lld:pubmed
pubmed-article:3067303pubmed:articleTitle[Blood pressure control and quality of life: a comparative multicenter double-blind and cross-over trial of labetalol and captopril].lld:pubmed
pubmed-article:3067303pubmed:affiliationService de médecine interne et hypertension artérielle, Hôpital cardiologique, Lille.lld:pubmed
pubmed-article:3067303pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3067303pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3067303pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:3067303pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:3067303pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:3067303pubmed:publicationTypeMulticenter Studylld:pubmed